Recent advances in understanding and managing psoriatic arthritis [version 1; referees: 2 approved]
This article reviews recent advances in psoriatic arthritis (PsA) over the past several years with emphasis on early diagnosis, better understanding of pathogenesis, and new therapeutic approaches. Early diagnosis is important, since people who present late do not fare as well. There are a number of...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2016-11-01
|
| Series: | F1000Research |
| Subjects: | |
| Online Access: | https://f1000research.com/articles/5-2670/v1 |
| _version_ | 1818556332126502912 |
|---|---|
| author | Dafna D. Gladman |
| author_facet | Dafna D. Gladman |
| author_sort | Dafna D. Gladman |
| collection | DOAJ |
| description | This article reviews recent advances in psoriatic arthritis (PsA) over the past several years with emphasis on early diagnosis, better understanding of pathogenesis, and new therapeutic approaches. Early diagnosis is important, since people who present late do not fare as well. There are a number of clinical, laboratory, and ultrasound features that can help identify patients destined to develop PsA, and several screening tools have been developed. It is recognized that genetic and epigenetic factors, as well as T cells and cytokines, play a role in the pathogenesis of PsA, and several targets have been identified for therapeutic interventions. New therapies have been developed and tested in PsA and have been found to be highly effective for both skin and joint manifestations of the disease. The expectation is that, in the future, PsA patients will be treated early and more aggressively and that there will not be significant progression of joint damage. Moreover, with effective treatment of the skin and joint disease and management of risk factors for the comorbidities, we can expect to reduce their occurrence and further reduce the excess mortality and reduced quality of life and function in these patients. |
| first_indexed | 2024-12-13T23:45:58Z |
| format | Article |
| id | doaj.art-aa31e18c9dcd4f95bb4e98587df76ff1 |
| institution | Directory Open Access Journal |
| issn | 2046-1402 |
| language | English |
| last_indexed | 2024-12-13T23:45:58Z |
| publishDate | 2016-11-01 |
| publisher | F1000 Research Ltd |
| record_format | Article |
| series | F1000Research |
| spelling | doaj.art-aa31e18c9dcd4f95bb4e98587df76ff12022-12-21T23:26:58ZengF1000 Research LtdF1000Research2046-14022016-11-01510.12688/f1000research.9592.110331Recent advances in understanding and managing psoriatic arthritis [version 1; referees: 2 approved]Dafna D. Gladman0Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, M5T 2S8, CanadaThis article reviews recent advances in psoriatic arthritis (PsA) over the past several years with emphasis on early diagnosis, better understanding of pathogenesis, and new therapeutic approaches. Early diagnosis is important, since people who present late do not fare as well. There are a number of clinical, laboratory, and ultrasound features that can help identify patients destined to develop PsA, and several screening tools have been developed. It is recognized that genetic and epigenetic factors, as well as T cells and cytokines, play a role in the pathogenesis of PsA, and several targets have been identified for therapeutic interventions. New therapies have been developed and tested in PsA and have been found to be highly effective for both skin and joint manifestations of the disease. The expectation is that, in the future, PsA patients will be treated early and more aggressively and that there will not be significant progression of joint damage. Moreover, with effective treatment of the skin and joint disease and management of risk factors for the comorbidities, we can expect to reduce their occurrence and further reduce the excess mortality and reduced quality of life and function in these patients.https://f1000research.com/articles/5-2670/v1Dermatologic PharmacologyGenetics of the Immune SystemImmune & Inflammatory Rheumatic Diseases (incl. Arthritis)Immunopharmacology & Hematologic PharmacologyInnate ImmunityMedical GeneticsMusculoskeletal PharmacologyPsoriasis & Other Inflammatory Diseases |
| spellingShingle | Dafna D. Gladman Recent advances in understanding and managing psoriatic arthritis [version 1; referees: 2 approved] F1000Research Dermatologic Pharmacology Genetics of the Immune System Immune & Inflammatory Rheumatic Diseases (incl. Arthritis) Immunopharmacology & Hematologic Pharmacology Innate Immunity Medical Genetics Musculoskeletal Pharmacology Psoriasis & Other Inflammatory Diseases |
| title | Recent advances in understanding and managing psoriatic arthritis [version 1; referees: 2 approved] |
| title_full | Recent advances in understanding and managing psoriatic arthritis [version 1; referees: 2 approved] |
| title_fullStr | Recent advances in understanding and managing psoriatic arthritis [version 1; referees: 2 approved] |
| title_full_unstemmed | Recent advances in understanding and managing psoriatic arthritis [version 1; referees: 2 approved] |
| title_short | Recent advances in understanding and managing psoriatic arthritis [version 1; referees: 2 approved] |
| title_sort | recent advances in understanding and managing psoriatic arthritis version 1 referees 2 approved |
| topic | Dermatologic Pharmacology Genetics of the Immune System Immune & Inflammatory Rheumatic Diseases (incl. Arthritis) Immunopharmacology & Hematologic Pharmacology Innate Immunity Medical Genetics Musculoskeletal Pharmacology Psoriasis & Other Inflammatory Diseases |
| url | https://f1000research.com/articles/5-2670/v1 |
| work_keys_str_mv | AT dafnadgladman recentadvancesinunderstandingandmanagingpsoriaticarthritisversion1referees2approved |